Human milk oligosaccharide compositions and applications that inhibit Escherichia coli adhesion to intestinal epithelial cells

By using a specific ratio of 2'-fucosylated lactose, lactose-N-neotetrasaccharide, and 6'-sialic acid lactose, the expression of Escherichia coli adhesion-related genes is inhibited, solving the problem of poor anti-E. coli adhesion effects in existing technologies and achieving protective effects on the intestinal mucosa and disease prevention and treatment.

CN123059062APending Publication Date: 2026-11-10BIOSTIME GUANGZHOU HEALTH PROD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510581528.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-07
Publication Date
2026-11-10

Smart Images

  • Figure CN123059062A_ABST
    Figure CN123059062A_ABST
Patent Text Reader

Abstract

This invention relates to the field of human milk oligosaccharide technology, and in particular to a human milk oligosaccharide composition and its application that inhibits Escherichia coli adhesion to intestinal epithelial cells. The composition comprises 2'-fucosylated lactose (2'-FL), lactose-N-neotetrasaccharide (LNnT), and 6'-sialic acid lactose (6'-SL) in a mass ratio of A:B:C. When 2'-fucosylated lactose, lactose-N-neotetrasaccharide, and 6'-sialic acid lactose are combined in a specific mass ratio, they exhibit superior anti-E. coli adhesion effects compared to equal amounts of breast milk or any single monomer of 2'-fucosylated lactose, lactose-N-neotetrasaccharide, or 6'-sialic acid lactose. The composition obtained by this invention possesses excellent resistance to harmful bacterial infections, and is particularly suitable for intestinal mucosal protection or repair in individuals with fragile intestinal mucosa, such as infants, the elderly, and patients with intestinal diseases. It can be used to prepare pharmaceuticals or foods for the prevention and treatment of intestinal diseases caused by Escherichia coli.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of human milk oligosaccharide technology, and in particular to a human milk oligosaccharide composition and its application that inhibits Escherichia coli adhesion to intestinal epithelial cells. Background Technology

[0002] Human milk oligosaccharides (HMOs) can act as soluble ligand analogs to inhibit the binding of various pathogens to cell surface receptors, thereby protecting breastfed infants from infection by different pathogens. They can also serve as prebiotics for symbiotic bacteria, maintaining the balance of the gut microbiota, regulating the immune system, and promoting brain development in infants and young children.

[0003] According to the article "Research Progress on the Relationship between Human Milk Oligosaccharides and Infant Health" (Food and Machinery, Vol. 40, No. 2, Serial No. 268, February 2024) by Jiang Yikang et al., enterotoxin-producing Escherichia coli and urinary tract pathogenic Escherichia coli recognize and bind to intestinal epithelial cell surface glycans through erythrocytes. Sialidized HMOs have a significant inhibitory effect on hemagglutination mediated by enterotoxin-producing Escherichia coli and urinary tract pathogenic Escherichia coli, thereby preventing their adhesion and colonization. Table 1 of the article records the types of HMOs in breast milk and their average mass concentration (g / L), among which 2'-fucosylated lactose (2'-FL), lactose-N-neotetrasaccharide (LNnT), and 6'-sialylated lactose (6'-SL) are 2.74, 0.79, and 0.64, respectively.

[0004] Escherichia coli poses various health risks to the human body, including intestinal infections, electrolyte imbalances, sepsis, and meningitis. In particular, intestinal infections are caused by E. coli damaging the intestinal mucosa, leading to inflammation and intestinal dysfunction.

[0005] Current technologies utilize breast milk or sialylated HMOs to inhibit E. coli adhesion to intestinal epithelial cells, thereby suppressing harmful bacterial adhesion and protecting the intestinal mucosa. However, practical experience shows that the anti-adhesion effect of existing technologies needs improvement. There is an urgent need for a breast milk oligosaccharide product that offers superior anti-E. coli adhesion compared to breast milk or sialylated HMOs, possessing better anti-infective properties than existing technologies, thus effectively protecting the delicate intestinal mucosa. Summary of the Invention

[0006] One objective of this invention is to provide a human milk oligosaccharide composition that inhibits Escherichia coli adhesion to intestinal epithelial cells. A second objective of this invention is to provide the use of the human milk oligosaccharide composition in the preparation of pharmaceuticals or foods that inhibit Escherichia coli adhesion. A third objective of this invention is to provide the use of the human milk oligosaccharide composition in the preparation of pharmaceuticals or foods that prevent and treat intestinal diseases caused by Escherichia coli, wherein the pharmaceuticals or foods can play an anti-infective and protective role for the intestinal mucosa.

[0007] One of the objectives of this invention is achieved through the following technical solution:

[0008] A human milk oligosaccharide composition for inhibiting Escherichia coli adhesion to intestinal epithelial cells, comprising 2'-fucosyllactose (2'-FL), lactose-N-neotetrasaccharide (LNnT), and 6'-sialyllactose (6'-SL) in a mass ratio of A:B:C; wherein 0.2667≤A≤0.4000, 0.2667≤B≤0.4000, 0.2667≤C≤0.4000, and A+B+C=1.

[0009] Furthermore, the ratio of A:B:C is 1:1:1.

[0010] The second objective of this invention is achieved through the following technical solution:

[0011] Use of human milk oligosaccharide compositions that inhibit Escherichia coli adhesion to intestinal epithelial cells in the preparation of pharmaceuticals or foods that inhibit Escherichia coli adhesion.

[0012] Furthermore, the human milk oligosaccharide composition inhibits the expression of adhesion-related genes nleB1, ibpB, ibpA, hcp, arcC, cydA, cydB, and gadA in Escherichia coli.

[0013] Furthermore, the *Escherichia coli* is *E. coli* O157:H7.

[0014] The third objective of this invention is achieved through the following technical solution:

[0015] Use of human milk oligosaccharide compositions that inhibit Escherichia coli adhesion to intestinal epithelial cells in the preparation of pharmaceuticals or foods for the prevention and treatment of intestinal diseases caused by Escherichia coli.

[0016] Furthermore, the human milk oligosaccharide composition can resist harmful bacterial infections of the intestines.

[0017] Furthermore, the human milk oligosaccharide composition can protect or repair the intestinal mucosa.

[0018] The beneficial effects of this invention are as follows:

[0019] This invention demonstrates through relative adhesion rate experiments that when 2'-fucosylated lactose, lactose-N-neotetraose, and 6'-sialylated lactose are combined in a specific mass ratio, they exhibit superior anti-Escherichia coli adhesion effects compared to an equal amount of breast milk or any single monomer of 2'-fucosylated lactose, lactose-N-neotetraose, or 6'-sialylated lactose.

[0020] Furthermore, transcriptomic experiments were used to verify the relative adhesion rate experiment, and the working principle of the invention was revealed at the molecular biology level: 2'-fucosylated lactose, lactose-N-neotetrasaccharide, and 6'-sialylated lactose, when combined in a specific mass ratio, inhibit the gene expression processes of *E. coli* in terms of nleB1, ibpA, ibpB, hcp, arcC, cydA, cydB, and gadA, thereby affecting bacterial heat stress and tolerance, influencing bacterial surface characteristics, regulating c-di-GMP signaling to affect adhesion, affecting the acid tolerance system, reducing virulence effects, and affecting host-cell interactions; ultimately making it difficult for *E. coli* to adhere and colonize the intestine.

[0021] In summary, the composition obtained by this invention has excellent resistance to harmful bacterial infections, and is especially suitable for the protection or repair of the intestinal mucosa of people with fragile intestinal mucosa, such as infants, the elderly, and patients with intestinal diseases. It can be used to prepare medicines or foods for the prevention and treatment of intestinal diseases caused by Escherichia coli. Attached Figure Description

[0022] Figure 1 The diagram shows the maximum regulatory effect of the composition of Example 1 on the following adhesion-related genes of Escherichia coli O157:H7.

[0023] In the figure, EPM (equal proportion mixture) represents the treatment group of Example 1. Detailed Implementation

[0024] The following is a further explanation with reference to specific implementation methods:

[0025] The mass ratios of the three components in Example 1 and Comparative Examples 1-4 are as follows:

[0026]

[0027]

[0028] Chemical reagents and materials:

[0029]

[0030] 1. Relative Adhesion Rate Experiment

[0031] 1. Experimental Methods

[0032] The cultured E. coli O157:H7 was washed and resuspended in medium containing 2% (v / v) FBS, to a final concentration of 1×10⁻⁶. 6CFU / mL. Samples (Examples 1 and Comparative Examples 1-4) were added to bacterial suspensions at a concentration of 10 mg / mL. Untreated bacterial suspensions served as the control group. These mixtures were incubated at 37°C and 5% CO2 for 1 hour, and then 1 mL was added to each HT-29 cell model for another 1 hour. After incubation, the cells were washed four times with PBS to remove unattached bacteria. To determine the number of bacteria adhering to the cells, HT-29 cells were lysed at 37°C using 0.1% (v / v) Triton X-100 solution. The resulting lysates were serially diluted 10-fold in Maximum Rejuvenating Dilution (MRD) and then inoculated onto MHA medium and incubated overnight at 37°C. Bacterial adhesion was quantified by counting colony-forming units (CFU) and expressed as a relative adhesion rate (%) compared to the control group.

[0033] 2. Experimental Results

[0034] Example 1: 7.84%;

[0035] Comparative Example 1: 16.87%;

[0036] Comparative Example 2: 12.53%;

[0037] Comparative Example 3: 11.06%;

[0038] Comparative Example 4: 12.02%.

[0039] 3. Conclusion

[0040] By treating *E. coli* with Examples 1 and Comparative Examples 1-4, and then comparing the adhesion of the treated bacterial cultures with those of untreated cultures, it was found that a ratio of 1:1:1 for 2'-fucosylated lactose, lactose-N-neotetraose, and 6'-sialic acid lactose significantly inhibited the adhesion rate of *E. coli*. This ratio was superior not only to any single monomer of 2'-fucosylated lactose, lactose-N-neotetraose, and 6'-sialic acid lactose, but also to Comparative Example 4, which closely resembled the composition of breast milk. It can be inferred without doubt that the specific ratio of 2'-fucosylated lactose, lactose-N-neotetraose, and 6'-sialic acid lactose has a positive effect on the adhesion of *E. coli*, and this effect is not simply the sum of the components.

[0041] II. Transcriptomics Experiments

[0042] 1. Experimental Methods

[0043] 1-1, RNA Extraction and Detection

[0044] 1-1-1, RNA extraction

[0045] Adjust the concentration of the overnight cultured bacterial suspension to 2×10⁻⁶. 6CFU / mL (5 groups in total), with equal volumes of 10 mg / mL sterile, membrane-passed bacterial suspension from Example 1 and Comparative Examples 1-3 added respectively. 1 mL of the treated bacterial suspension was added to each enzyme-free centrifuge tube, with a blank bacterial suspension used as a control. Each treatment was performed in triplicate. Total RNA was extracted from each sample using a column-based bacterial total RNA extraction and purification kit. Following the kit's instructions, bacteria in the logarithmic growth phase were collected by centrifugation at 4°C and 8,000 rpm for 1 min. The supernatant was discarded, and the bacterial pellet was resuspended in 100 μL of lysozyme solution (400 μg / mL) and incubated at room temperature for 5 min. Subsequently, the bacterial suspension was lysed using Rlysis-BG lysis buffer, treated with anhydrous ethanol, allowed to stand for 1 min, and centrifuged at 12,000 rpm for 1 min at room temperature. The waste liquid in the collection tube was discarded, and the RNA was bound to the centrifuge column. Subsequently, the sample was washed sequentially with GT and NT buffers and allowed to stand for 1 min. It was then centrifuged at 10,000 rpm for 1 min at room temperature. The waste liquid in the collection tube was discarded, and the total RNA was finally eluted with 50 μL of diethyl pyrocarbonate (DEPC).

[0046] 1-1-2, RNA quality and concentration determination

[0047] The extracted total RNA was then immediately placed on ice, and its concentration and purity were determined using a NanoDrop 2000C spectrophotometer. RNA integrity was analyzed by agarose gel electrophoresis, and further validation was performed using an Agilent 2100 bioanalyzer.

[0048] 1-2, Library Construction and Quality Inspection

[0049] rRNA was removed from extracted bacterial total RNA using the Zymo-Seq RiboFree Total RNA Library Kit for Illumina sequencing. The RNA was then randomly fragmented using divalent cations. The RNA was subsequently fragmented, and complementary DNA (cDNA) was synthesized via reverse transcription using the RNA as a template. The resulting double-stranded cDNA was purified and screened for 400-500 bp fragments using the AMPure XP Nucleic Acid Purification Kit. Subsequent steps included paired-end repair, insertion of an A base at the 3' end, and ligation with sequencing adapters. The resulting product was then amplified by polymerase chain reaction (PCR), and the PCR product was purified again using AMPure XP beads to obtain the final library.

[0050] Library quality was assessed using a bioanalyzer and a high-sensitivity DNA kit. The Quant-iT PicoGreends DNA quantification kit was used to measure the total library concentration, and qPCR quantification was used to quantify the effective library concentration. Multiplexed DNA libraries were homogenized and mixed in equal volumes. The mixed libraries were then stepwise diluted and quantified, and finally sequenced on an Illumina sequencer in PE150 mode.

[0051] 1-3, Transcriptome Analysis

[0052] 1-3-1, Data Quality Control

[0053] The image files generated by sequencing were converted into FASTQ raw data using software provided by the sequencing platform. Sequences with 3' bifurcations were removed by using fastp (0.22.0) and reads with an average quality score lower than Q20. This further filtered out some sequences with adapters and low quality, preventing them from causing significant interference to subsequent information analysis. As a result, all subsequent analyses were high-quality analyses based on clean data.

[0054] 1-3-2, Alignment and Gene Expression Analysis

[0055] As a prokaryote, E. coli O157:H7 transcriptome data was used to construct a reference genome index using Bowtie2 (v2.4.1) and the filtered sequences were compared with the reference genome.

[0056] HTSeq (v0.9.1) was used to statistically compare the read count values ​​of each gene in E. coli as the raw gene expression level. To ensure comparability of gene expression levels between different genes and different samples, expression levels were normalized using Fragments Per Kilo bases Per Million fragments (FPKM).

[0057] The FPKM calculation formula is as follows:

[0058]

[0059] 1-3-3, Differential Gene Expression and Enrichment Analysis

[0060] Differentially expressed genes (DEGs) were screened using DESeq2 (v1.38.3), with DEGs meeting the criteria of |log2FoldChange|>1 and a significance p<0.05. Further GO enrichment analysis was performed using topGO, and p-values ​​were calculated using hypergeometric distribution. GO terms showing significant enrichment (p<0.05) were selected for upregulation, downregulation, and all differentially expressed genes. KEGG pathway enrichment analysis was performed using clusterProfiler (v4.6.0), again focusing on significantly enriched pathways (p<0.05) to determine the main biological functions of differentially expressed genes.

[0061] 2. Experimental Results

[0062] See the gene expression fold change table, gene expression difference table and Figure 1 .

[0063] Logarithmic table of gene expression fold changes:

[0064]

[0065]

[0066] Gene expression fold change table:

[0067]

[0068] 3. Conclusion

[0069] Transcriptomic results further confirmed the accuracy of the "relative adhesion rate experiment". By treating *E. coli* with Example 1 and Comparative Examples 1-3, it was found that 2'-fucosylated lactose treatment had no significant inhibitory effect on arcC and gadA, lactose-N-neotetrasaccharide treatment had no significant inhibitory effect on cydA, and 6'-sialylated lactose had no significant inhibitory effect on arcC and gadA; while Example 1 showed a strong inhibitory effect on the expression of nleB1, ibpA, ibpB, hcp, arcC, cydA, cydB, and gadA. This reveals the working principle of the invention from a molecular biological perspective.

[0070] The embodiments and descriptions above are merely illustrative of the principles and preferred embodiments of the present invention. Various changes and modifications may be made to the present invention without departing from its spirit and scope, and all such changes and modifications fall within the scope of the present invention as claimed.

Claims

1. A human milk oligosaccharide composition that inhibits Escherichia coli adhesion to intestinal epithelial cells, characterized in that, It includes 2'-fucosyllactose, lactose-N-neotetrasaccharide, and 6'-sialyllactose in a mass ratio of A:B:C; wherein 0.2667≤A≤0.4000, 0.2667≤B≤0.4000, 0.2667≤C≤0.4000, and A+B+C=1.

2. The human milk oligosaccharide composition for inhibiting Escherichia coli adhesion to intestinal epithelial cells according to claim 1, characterized in that: The ratio of A:B:C is 1:1:

1.

3. The use of the human milk oligosaccharide composition for preventing Escherichia coli adhesion to intestinal epithelial cells according to claim 1 in the preparation of pharmaceuticals or foods for preventing Escherichia coli adhesion.

4. The application according to claim 3, characterized in that, The human milk oligosaccharide composition inhibits the expression of adhesion-related genes nleB1, ibpB, ibpA, hcp, arcC, cydB, cydA and gadA in Escherichia coli.

5. The application according to claim 4, characterized in that, The Escherichia coli was E. coli O157:H7.

6. The use of the human milk oligosaccharide composition according to claim 1, which is effective against Escherichia coli adhesion to intestinal epithelial cells, in the preparation of pharmaceuticals or foods for the prevention and treatment of intestinal diseases caused by Escherichia coli.

7. The human milk oligosaccharide composition according to claim 6 can resist harmful bacterial infections of the intestines.

8. The human milk oligosaccharide composition according to claim 6 can protect or repair the intestinal mucosa.